Floxipar200 mg

Floxipar is a broad-spectrum fluoroquinolone antibacterial used to treat certain bacterial infections caused by susceptible organisms in adults. Because of its phototoxicity and QT-prolongation risk, it is generally reserved for situations where more established antibiotics are unsuitable, and treatment should be guided by culture and susceptibility testing where possible.

Established / guideline-supported uses

• Community-acquired pneumonia (CAP) caused by susceptible bacteria.
• Acute bacterial exacerbation of chronic bronchitis (AECB) in patients with underlying chronic obstructive pulmonary disease.
• Acute bacterial maxillary sinusitis caused by susceptible organisms.

Adjunct / combination-therapy use

• As part of multidrug regimens for tuberculosis or leprosy in select cases where first-line agents cannot be used; Floxipar is not used as monotherapy for these conditions and must be combined with other anti-mycobacterial agents under specialist supervision.

Off-label / less-established use

• Complicated urinary tract infections and bacterial prostatitis, where local resistance patterns support its use — considered off-label/second-line in most current guidance given the availability of safer fluoroquinolones.

Floxipar should only be used for infections proven or strongly suspected to be caused by susceptible bacteria, in line with antibiotic stewardship principles.

Each film-coated tablet contains Sparfloxacin INN 200 mg, along with pharmaceutical excipients q.s. Strength and exact formulation may vary slightly by manufacturer; always check the product label of the specific brand dispensed.

Floxipar is a synthetic, broad-spectrum fluoroquinolone antibacterial agent. It belongs to an older generation of fluoroquinolones and is distinguished from many other agents in this class by a markedly higher risk of phototoxic skin reactions and a notable potential to prolong the cardiac QT interval, both of which have led to restricted use or market withdrawal in a number of countries. Where it remains available, including in Bangladesh, it is used for selected respiratory and other bacterial infections when the prescribing physician judges the benefit outweighs these risks.

Fluoroquinolone group of antibacterials (broad-spectrum, third-generation fluoroquinolone)

Sparfloxacin is bactericidal, acting by inhibition of bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, and repair. This action prevents bacterial cell division and leads to cell death. It has broad activity against many gram-positive and gram-negative organisms as well as atypical pathogens such as Mycoplasma and Chlamydia species.

Pharmacokinetics

• Absorption: Well absorbed orally (bioavailability approximately 90%); peak plasma concentration reached within a few hours. Food does not significantly affect absorption, but co-administered antacids/multivalent cation products markedly reduce absorption.
• Distribution: Large volume of distribution with good penetration into respiratory tissue and fluids; plasma protein binding is low-to-moderate.
• Metabolism: Undergoes hepatic glucuronidation; minimal involvement of cytochrome P450 enzymes.
• Elimination: Eliminated via both renal and biliary/fecal routes, with a long elimination half-life supporting once-daily dosing.

Take Floxipar tablets orally with a full glass of water, with or without food, at approximately the same time each day. Do not take it together with antacids or mineral supplements (aluminum, magnesium, iron, zinc, calcium) — separate these by at least 4 hours. Drink adequate fluids throughout treatment and avoid unnecessary sun or UV light exposure while taking Floxipar.

Floxipar has several clinically important drug interactions:

• QT-prolonging drugs: Concurrent use with other agents that prolong the QT interval (certain antiarrhythmics such as amiodarone and quinidine, certain antipsychotics, tricyclic antidepressants, and some macrolide antibiotics) increases the risk of serious cardiac arrhythmia and should be avoided.
• Antacids and multivalent cations: Products containing aluminum, magnesium, calcium, iron, or zinc (including many antacids and mineral supplements) form chelation complexes with Floxipar and substantially reduce its absorption; separate dosing by at least 4 hours.
• Corticosteroids: Concomitant systemic corticosteroid use increases the risk of tendinitis and tendon rupture, particularly in elderly patients.
• Theophylline: Caution is advised with concurrent theophylline, as fluoroquinolone-class interactions can alter theophylline levels; monitor for toxicity if co-administered.

Most side effects of Floxipar are mild to moderate and transient, but some are serious and require prompt medical attention.

Common

• Photosensitivity/phototoxicity: notably more frequent and more severe with Floxipar than with many other fluoroquinolones — presents as exaggerated sunburn-like reaction; sun/UV exposure should be avoided.
• Nausea, diarrhea, dyspepsia, abdominal pain, vomiting, flatulence.
• Headache, dizziness, insomnia.
• Taste disturbance, itching (pruritus).

Less common but serious

• QT interval prolongation and, rarely, serious cardiac arrhythmia.
• Tendinitis and tendon rupture (see Precautions).
• Peripheral neuropathy.
• CNS effects: confusion, hallucinations, seizures (rare).
• Hypersensitivity reactions, including severe skin reactions.

Floxipar is generally contraindicated in pregnancy and during breastfeeding. Fluoroquinolones as a class have been associated with effects on developing cartilage in animal studies, and adequate, well-controlled studies in pregnant women are lacking. Floxipar should be used in pregnancy only if the physician determines there is no suitable alternative and the potential benefit clearly justifies the potential risk to the fetus. Floxipar passes into breast milk; breastfeeding is not recommended during treatment. Always consult a physician before using Floxipar if pregnant, planning pregnancy, or breastfeeding.

Floxipar carries several important fluoroquinolone class warnings in addition to indication-specific cautions:

• Phototoxicity: Moderate to severe phototoxic reactions can occur with sun or UV light exposure, even through window glass or on cloudy days. Avoid direct sunlight and sunlamps during treatment and for several days after the last dose; discontinue and seek medical advice if burning, redness, swelling, blistering, or rash occurs.
• Tendinitis and tendon rupture: Risk is increased in patients over 60 years, those taking corticosteroids, and organ transplant recipients. Stop Floxipar and rest the affected area immediately if pain, swelling, or inflammation of a tendon occurs.
• Peripheral neuropathy: Fluoroquinolones can cause sensory or sensorimotor peripheral neuropathy, which may be irreversible; discontinue if symptoms of numbness, tingling, pain, burning, or weakness develop.
• Central nervous system effects: May cause dizziness, confusion, tremors, and rarely seizures or hallucinations; use with caution in patients with known CNS disorders.
• QT prolongation: Use with caution in patients with cardiac disease, electrolyte disturbances, or concomitant use of QT-prolonging drugs (see Contraindications and Interactions).
• Myasthenia gravis: Fluoroquinolones can worsen muscle weakness and are contraindicated in this condition.
• Antibiotic stewardship: Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

In case of suspected Floxipar overdose, seek immediate medical attention or contact a poison control center/emergency services. Overdose may cause exaggerated side effects, including severe nausea and vomiting, dizziness, and cardiac rhythm disturbances (QT prolongation). There is no specific antidote; management is supportive and symptomatic, typically including gastric decontamination if presenting soon after ingestion, adequate hydration, and cardiac monitoring, under medical supervision. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

• Renal impairment: Dose adjustment required for creatinine clearance below 50 mL/min (200 mg every 48 hours after the loading dose); plasma concentrations may approximately double.
• Hepatic impairment: No dose adjustment is generally required in mild-to-moderate hepatic impairment; use with caution and physician judgment in severe impairment.
• Elderly: No specific pharmacokinetic dose adjustment is needed with normal renal function, but elderly patients have a higher risk of tendon injury and QT-related effects and should be monitored closely.
• Pediatric patients: Not recommended for use under 18 years (see Pediatric Uses).
• G6PD deficiency: Contraindicated due to risk of hemolysis (see Contraindications).

Duration of Floxipar therapy depends on the indication being treated, but is typically 10 days in total (including the loading dose day) for community-acquired pneumonia and acute exacerbation of chronic bronchitis. Duration for sinusitis and other indications should follow the treating physician's advice. The full prescribed course should always be completed even if symptoms improve earlier, unless directed otherwise by a physician.

Fluoroquinolone antibacterials

Sparfloxacin exerts its bactericidal effect by inhibiting two essential bacterial enzymes, DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are required for the supercoiling, replication, transcription, and repair of bacterial DNA. By blocking their activity, Sparfloxacin disrupts bacterial DNA synthesis, leading to rapid bacterial cell death. This mechanism gives it activity against a broad range of gram-positive and gram-negative bacteria as well as certain atypical organisms.

C (legacy FDA pregnancy category; use in pregnancy is generally contraindicated — see Pregnancy and Lactation)

Safety and efficacy of Floxipar in children and adolescents under 18 years have not been established. As with other fluoroquinolones, animal studies have shown an association with arthropathy (joint/cartilage damage) in immature animals, raising a theoretical concern for developing joints and cartilage in children. Floxipar is therefore not recommended for use in patients under 18 years except in rare situations where a physician determines the benefit clearly outweighs this risk and no suitable alternative is available.